Global Antidiabetic Biguanides Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Global Antidiabetic Biguanides Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Antidiabetic Biguanides Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Metformin IR
1.2.3 Metformin SR
1.3 Market Segment by Application
1.3.1 Global Antidiabetic Biguanides Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Antidiabetic Biguanides Market Size (2017-2028)
2.1.1 Global Antidiabetic Biguanides Revenue (2017-2028)
2.1.2 Global Antidiabetic Biguanides Sales (2017-2028)
2.2 Global Antidiabetic Biguanides Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Antidiabetic Biguanides Sales by Regions (2017-2022)
2.2.2 Global Antidiabetic Biguanides Revenue by Regions (2017-2022)
2.3 Global Antidiabetic Biguanides Market Size Forecast by Region
2.3.1 Global Antidiabetic Biguanides Sales Forecast by Region (2023-2028)
2.3.2 Global Antidiabetic Biguanides Revenue Forecast by Region (2023-2028)
2.4 Global Top Antidiabetic Biguanides Regions (Countries) Ranking by Market Size
2.5 Antidiabetic Biguanides Market Dynamics
2.5.1 Antidiabetic Biguanides Market Trends
2.5.2 Antidiabetic Biguanides Market Drivers
2.5.3 Antidiabetic Biguanides Market Challenges
2.5.4 Antidiabetic Biguanides Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Antidiabetic Biguanides Manufacturers by Sales (2017-2022)
3.1.1 Global Antidiabetic Biguanides Sales by Manufacturers (2017-2022)
3.1.2 Global Antidiabetic Biguanides Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Antidiabetic Biguanides Sales in 2021
3.2 Global Top Manufacturers Antidiabetic Biguanides by Revenue
3.2.1 Global Antidiabetic Biguanides Revenue by Manufacturers (2017-2022)
3.2.2 Top Antidiabetic Biguanides Manufacturers Covered: Ranking by Revenue
3.2.3 Global Antidiabetic Biguanides Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Antidiabetic Biguanides Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antidiabetic Biguanides as of 2021)
3.4 Global Antidiabetic Biguanides Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Antidiabetic Biguanides Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Antidiabetic Biguanides Market
3.7 Key Manufacturers Antidiabetic Biguanides Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Antidiabetic Biguanides Market Size by Type
4.1 Global Antidiabetic Biguanides Historic Market Review by Type (2017-2022)
4.1.1 Global Antidiabetic Biguanides Sales Market Share by Type (2017-2022)
4.1.2 Global Antidiabetic Biguanides Revenue Market Share by Type (2017-2022)
4.1.3 Antidiabetic Biguanides Price by Type (2017-2022)
4.2 Global Antidiabetic Biguanides Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Antidiabetic Biguanides Sales Forecast by Type (2023-2028)
4.2.2 Global Antidiabetic Biguanides Revenue Forecast by Type (2023-2028)
4.2.3 Antidiabetic Biguanides Price Forecast by Type (2023-2028)
5 Global Antidiabetic Biguanides Market Size by Application
5.1 Global Antidiabetic Biguanides Historic Market Review by Application (2017-2022)
5.1.1 Global Antidiabetic Biguanides Sales Market Share by Application (2017-2022)
5.1.2 Global Antidiabetic Biguanides Revenue Market Share by Application (2017-2022)
5.1.3 Antidiabetic Biguanides Price by Application (2017-2022)
5.2 Global Antidiabetic Biguanides Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Antidiabetic Biguanides Sales Forecast by Application (2023-2028)
5.2.2 Global Antidiabetic Biguanides Revenue Forecast by Application (2023-2028)
5.2.3 Antidiabetic Biguanides Price Forecast by Application (2023-2028)
6 North America
6.1 North America Antidiabetic Biguanides Sales Breakdown by Company
6.1.1 North America Antidiabetic Biguanides Sales by Company (2017-2022)
6.1.2 North America Antidiabetic Biguanides Revenue by Company (2017-2022)
6.2 North America Antidiabetic Biguanides Market Size by Type
6.2.1 North America Antidiabetic Biguanides Sales by Type (2017-2028)
6.2.2 North America Antidiabetic Biguanides Revenue by Type (2017-2028)
6.3 North America Antidiabetic Biguanides Market Size by Application
6.3.1 North America Antidiabetic Biguanides Sales by Application (2017-2028)
6.3.2 North America Antidiabetic Biguanides Revenue by Application (2017-2028)
6.4 North America Antidiabetic Biguanides Market Size by Country
6.4.1 North America Antidiabetic Biguanides Sales by Country (2017-2028)
6.4.2 North America Antidiabetic Biguanides Revenue by Country (2017-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Antidiabetic Biguanides Sales Breakdown by Company
7.1.1 Europe Antidiabetic Biguanides Sales by Company (2017-2022)
7.1.2 Europe Antidiabetic Biguanides Revenue by Company (2017-2022)
7.2 Europe Antidiabetic Biguanides Market Size by Type
7.2.1 Europe Antidiabetic Biguanides Sales by Type (2017-2028)
7.2.2 Europe Antidiabetic Biguanides Revenue by Type (2017-2028)
7.3 Europe Antidiabetic Biguanides Market Size by Application
7.3.1 Europe Antidiabetic Biguanides Sales by Application (2017-2028)
7.3.2 Europe Antidiabetic Biguanides Revenue by Application (2017-2028)
7.4 Europe Antidiabetic Biguanides Market Size by Country
7.4.1 Europe Antidiabetic Biguanides Sales by Country (2017-2028)
7.4.2 Europe Antidiabetic Biguanides Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Antidiabetic Biguanides Sales Breakdown by Company
8.1.1 Asia Pacific Antidiabetic Biguanides Sales by Company (2017-2022)
8.1.2 Asia Pacific Antidiabetic Biguanides Revenue by Company (2017-2022)
8.2 Asia Pacific Antidiabetic Biguanides Market Size by Type
8.2.1 Asia Pacific Antidiabetic Biguanides Sales by Type (2017-2028)
8.2.2 Asia Pacific Antidiabetic Biguanides Revenue by Type (2017-2028)
8.3 Asia Pacific Antidiabetic Biguanides Market Size by Application
8.3.1 Asia Pacific Antidiabetic Biguanides Sales by Application (2017-2028)
8.3.2 Asia Pacific Antidiabetic Biguanides Revenue by Application (2017-2028)
8.4 Asia Pacific Antidiabetic Biguanides Market Size by Region
8.4.1 Asia Pacific Antidiabetic Biguanides Sales by Region
8.4.2 Asia Pacific Antidiabetic Biguanides Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 China Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
9 Latin America
9.1 Latin America Antidiabetic Biguanides Sales Breakdown by Company
9.1.1 Latin America Antidiabetic Biguanides Sales by Company (2017-2022)
9.1.2 Latin America Antidiabetic Biguanides Revenue by Company (2017-2022)
9.2 Latin America Antidiabetic Biguanides Market Size by Type
9.2.1 Latin America Antidiabetic Biguanides Sales by Type (2017-2028)
9.2.2 Latin America Antidiabetic Biguanides Revenue by Type (2017-2028)
9.3 Latin America Antidiabetic Biguanides Market Size by Application
9.3.1 Latin America Antidiabetic Biguanides Sales by Application (2017-2028)
9.3.2 Latin America Antidiabetic Biguanides Revenue by Application (2017-2028)
9.4 Latin America Antidiabetic Biguanides Market Size by Country
9.4.1 Latin America Antidiabetic Biguanides Sales by Country (2017-2028)
9.4.2 Latin America Antidiabetic Biguanides Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Antidiabetic Biguanides Sales Breakdown by Company
10.1.1 Middle East and Africa Antidiabetic Biguanides Sales by Company (2017-2022)
10.1.2 Middle East and Africa Antidiabetic Biguanides Revenue by Company (2017-2022)
10.2 Middle East and Africa Antidiabetic Biguanides Market Size by Type
10.2.1 Middle East and Africa Antidiabetic Biguanides Sales by Type (2017-2028)
10.2.2 Middle East and Africa Antidiabetic Biguanides Revenue by Type (2017-2028)
10.3 Middle East and Africa Antidiabetic Biguanides Market Size by Application
10.3.1 Middle East and Africa Antidiabetic Biguanides Sales by Application (2017-2028)
10.3.2 Middle East and Africa Antidiabetic Biguanides Revenue by Application (2017-2028)
10.4 Middle East and Africa Antidiabetic Biguanides Market Size by Country
10.4.1 Middle East and Africa Antidiabetic Biguanides Sales by Country (2017-2028)
10.4.2 Middle East and Africa Antidiabetic Biguanides Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Pfizer Antidiabetic Biguanides Products and Services
11.1.5 Pfizer Antidiabetic Biguanides SWOT Analysis
11.1.6 Pfizer Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 AstraZeneca Antidiabetic Biguanides Products and Services
11.2.5 AstraZeneca Antidiabetic Biguanides SWOT Analysis
11.2.6 AstraZeneca Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Overview
11.3.3 GlaxoSmithKline Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 GlaxoSmithKline Antidiabetic Biguanides Products and Services
11.3.5 GlaxoSmithKline Antidiabetic Biguanides SWOT Analysis
11.3.6 GlaxoSmithKline Recent Developments
11.4 Merck & Co
11.4.1 Merck & Co Corporation Information
11.4.2 Merck & Co Overview
11.4.3 Merck & Co Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 Merck & Co Antidiabetic Biguanides Products and Services
11.4.5 Merck & Co Antidiabetic Biguanides SWOT Analysis
11.4.6 Merck & Co Recent Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Corporation Information
11.5.2 Eli Lilly Overview
11.5.3 Eli Lilly Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Eli Lilly Antidiabetic Biguanides Products and Services
11.5.5 Eli Lilly Antidiabetic Biguanides SWOT Analysis
11.5.6 Eli Lilly Recent Developments
11.6 Sanofi
11.6.1 Sanofi Corporation Information
11.6.2 Sanofi Overview
11.6.3 Sanofi Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Sanofi Antidiabetic Biguanides Products and Services
11.6.5 Sanofi Antidiabetic Biguanides SWOT Analysis
11.6.6 Sanofi Recent Developments
11.7 Takeda Pharmaceuticals
11.7.1 Takeda Pharmaceuticals Corporation Information
11.7.2 Takeda Pharmaceuticals Overview
11.7.3 Takeda Pharmaceuticals Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Takeda Pharmaceuticals Antidiabetic Biguanides Products and Services
11.7.5 Takeda Pharmaceuticals Antidiabetic Biguanides SWOT Analysis
11.7.6 Takeda Pharmaceuticals Recent Developments
11.8 Novo Nordisk
11.8.1 Novo Nordisk Corporation Information
11.8.2 Novo Nordisk Overview
11.8.3 Novo Nordisk Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Novo Nordisk Antidiabetic Biguanides Products and Services
11.8.5 Novo Nordisk Antidiabetic Biguanides SWOT Analysis
11.8.6 Novo Nordisk Recent Developments
11.9 Servier Laboratories
11.9.1 Servier Laboratories Corporation Information
11.9.2 Servier Laboratories Overview
11.9.3 Servier Laboratories Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 Servier Laboratories Antidiabetic Biguanides Products and Services
11.9.5 Servier Laboratories Antidiabetic Biguanides SWOT Analysis
11.9.6 Servier Laboratories Recent Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Corporation Information
11.10.2 Boehringer Ingelheim Overview
11.10.3 Boehringer Ingelheim Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 Boehringer Ingelheim Antidiabetic Biguanides Products and Services
11.10.5 Boehringer Ingelheim Antidiabetic Biguanides SWOT Analysis
11.10.6 Boehringer Ingelheim Recent Developments
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Corporation Information
11.11.2 Bristol-Myers Squibb Overview
11.11.3 Bristol-Myers Squibb Antidiabetic Biguanides Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 Bristol-Myers Squibb Antidiabetic Biguanides Products and Services
11.11.5 Bristol-Myers Squibb Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Antidiabetic Biguanides Value Chain Analysis
12.2 Antidiabetic Biguanides Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antidiabetic Biguanides Production Mode & Process
12.4 Antidiabetic Biguanides Sales and Marketing
12.4.1 Antidiabetic Biguanides Sales Channels
12.4.2 Antidiabetic Biguanides Distributors
12.5 Antidiabetic Biguanides Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Antidiabetic Biguanides Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Metformin IR
Table 3. Major Manufacturers of Metformin SR
Table 4. Global Antidiabetic Biguanides Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Antidiabetic Biguanides Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 6. Global Antidiabetic Biguanides Sales by Region (2017-2022) & (K Pcs)
Table 7. Global Antidiabetic Biguanides Sales Market Share by Region (2017-2022)
Table 8. Global Antidiabetic Biguanides Revenue by Region (2017-2022) & (US$ Million)
Table 9. Global Antidiabetic Biguanides Revenue Market Share by Region (2017-2022)
Table 10. Global Antidiabetic Biguanides Sales Forecast by Region (2023-2028) & (K Pcs)
Table 11. Global Antidiabetic Biguanides Sales Market Share Forecast by Region (2023-2028)
Table 12. Global Antidiabetic Biguanides Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 13. Global Antidiabetic Biguanides Revenue Market Share Forecast by Region (2023-2028)
Table 14. Top Antidiabetic Biguanides Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 15. Antidiabetic Biguanides Market Trends
Table 16. Antidiabetic Biguanides Market Drivers
Table 17. Antidiabetic Biguanides Market Challenges
Table 18. Antidiabetic Biguanides Market Restraints
Table 19. Global Antidiabetic Biguanides Sales by Manufacturers (2017-2022) & (K Pcs)
Table 20. Global Antidiabetic Biguanides Sales Share by Manufacturers (2017-2022)
Table 21. Global Antidiabetic Biguanides Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 22. Ranking of Global Top Antidiabetic Biguanides Manufacturers by Revenue (US$ Million) in 2021
Table 23. Antidiabetic Biguanides Revenue Share by Manufacturers (2017-2022)
Table 24. Global Antidiabetic Biguanides Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antidiabetic Biguanides as of 2021)
Table 26. Key Manufacturers Antidiabetic Biguanides Average Selling Price (ASP) & (2017-2022) & (USD/Pcs)
Table 27. Key Manufacturers Antidiabetic Biguanides Plants/Factories Distribution
Table 28. Key Manufacturers Antidiabetic Biguanides Area Served
Table 29. Date of Key Manufacturers Enter into Antidiabetic Biguanides Market
Table 30. Key Manufacturers Antidiabetic Biguanides Product Type
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Antidiabetic Biguanides Sales (K Pcs) by Type (2017-2022)
Table 33. Global Antidiabetic Biguanides Sales Share by Type (2017-2022)
Table 34. Global Antidiabetic Biguanides Revenue (US$ Million) Market Share by Type (2017-2022)
Table 35. Global Antidiabetic Biguanides Price (K Pcs) by Type (2017-2022)
Table 36. Global Antidiabetic Biguanides Sales (K Pcs) by Type (2023-2028)
Table 37. Global Antidiabetic Biguanides Sales Share by Type (2023-2028)
Table 38. Global Antidiabetic Biguanides Revenue (US$ Million) Market Share by Type (2023-2028)
Table 39. Global Antidiabetic Biguanides Revenue Share by Type (2023-2028)
Table 40. Global Antidiabetic Biguanides Price (K Pcs) by Type (2023-2028)
Table 41. Global Antidiabetic Biguanides Sales (K Pcs) by Application (2017-2022)
Table 42. Global Antidiabetic Biguanides Sales Share by Application (2017-2022)
Table 43. Global Antidiabetic Biguanides Revenue (US$ Million) Market Share by Application (2017-2022)
Table 44. Global Antidiabetic Biguanides Price (K Pcs) by Application (2017-2022)
Table 45. Global Antidiabetic Biguanides Sales (K Pcs) by Application (2023-2028)
Table 46. Global Antidiabetic Biguanides Sales Share by Application (2023-2028)
Table 47. Global Antidiabetic Biguanides Revenue (US$ Million) Market Share by Application (2023-2028)
Table 48. Global Antidiabetic Biguanides Revenue Share by Application (2023-2028)
Table 49. Global Antidiabetic Biguanides Price (K Pcs) by Application (2023-2028)
Table 50. North America Antidiabetic Biguanides Sales by Company (2017-2022) & (K Pcs)
Table 51. North America Antidiabetic Biguanides Sales Market Share by Company (2017-2022)
Table 52. North America Antidiabetic Biguanides Revenue by Company (2017-2022) & (US$ Million)
Table 53. North America Antidiabetic Biguanides Revenue Market Share by Company (2017-2022)
Table 54. North America Antidiabetic Biguanides Sales by Type (2017-2022) & (K Pcs)
Table 55. North America Antidiabetic Biguanides Sales by Type (2023-2028) & (K Pcs)
Table 56. North America Antidiabetic Biguanides Revenue by Type (2017-2022) & (US$ Million)
Table 57. North America Antidiabetic Biguanides Revenue by Type (2023-2028) & (US$ Million)
Table 58. North America Antidiabetic Biguanides Sales by Application (2017-2022) & (K Pcs)
Table 59. North America Antidiabetic Biguanides Sales by Application (2023-2028) & (K Pcs)
Table 60. North America Antidiabetic Biguanides Revenue by Application (2017-2022) & (US$ Million)
Table 61. North America Antidiabetic Biguanides Revenue by Application (2023-2028) & (US$ Million)
Table 62. North America Antidiabetic Biguanides Sales by Country (2017-2022) & (K Pcs)
Table 63. North America Antidiabetic Biguanides Sales by Country (2023-2028) & (K Pcs)
Table 64. North America Antidiabetic Biguanides Revenue by Country (2017-2022) & (US$ Million)
Table 65. North America Antidiabetic Biguanides Revenue by Country (2023-2028) & (US$ Million)
Table 66. Europe Antidiabetic Biguanides Sales by Company (2017-2022) & (K Pcs)
Table 67. Europe Antidiabetic Biguanides Sales Market Share by Company (2017-2022)
Table 68. Europe Antidiabetic Biguanides Revenue by Company (2017-2022) & (US$ Million)
Table 69. Europe Antidiabetic Biguanides Revenue Market Share by Company (2017-2022)
Table 70. Europe Antidiabetic Biguanides Sales by Type (2017-2022) & (K Pcs)
Table 71. Europe Antidiabetic Biguanides Sales by Type (2023-2028) & (K Pcs)
Table 72. Europe Antidiabetic Biguanides Revenue by Type (2017-2022) & (US$ Million)
Table 73. Europe Antidiabetic Biguanides Revenue by Type (2023-2028) & (US$ Million)
Table 74. Europe Antidiabetic Biguanides Sales by Application (2017-2022) & (K Pcs)
Table 75. Europe Antidiabetic Biguanides Sales by Application (2023-2028) & (K Pcs)
Table 76. Europe Antidiabetic Biguanides Revenue by Application (2017-2022) & (US$ Million)
Table 77. Europe Antidiabetic Biguanides Revenue by Application (2023-2028) & (US$ Million)
Table 78. Europe Antidiabetic Biguanides Sales by Country (2017-2022) & (K Pcs)
Table 79. Europe Antidiabetic Biguanides Sales by Country (2023-2028) & (K Pcs)
Table 80. Europe Antidiabetic Biguanides Revenue by Country (2017-2022) & (US$ Million)
Table 81. Europe Antidiabetic Biguanides Revenue by Country (2023-2028) & (US$ Million)
Table 82. Asia Pacific Antidiabetic Biguanides Sales by Company (2017-2022) & (K Pcs)
Table 83. Asia Pacific Antidiabetic Biguanides Sales Market Share by Company (2017-2022)
Table 84. Asia Pacific Antidiabetic Biguanides Revenue by Company (2017-2022) & (US$ Million)
Table 85. Asia Pacific Antidiabetic Biguanides Revenue Market Share by Company (2017-2022)
Table 86. Asia Pacific Antidiabetic Biguanides Sales by Type (2017-2022) & (K Pcs)
Table 87. Asia Pacific Antidiabetic Biguanides Sales by Type (2023-2028) & (K Pcs)
Table 88. Asia Pacific Antidiabetic Biguanides Revenue by Type (2017-2022) & (US$ Million)
Table 89. Asia Pacific Antidiabetic Biguanides Revenue by Type (2023-2028) & (US$ Million)
Table 90. Asia Pacific Antidiabetic Biguanides Sales by Application (2017-2022) & (K Pcs)
Table 91. Asia Pacific Antidiabetic Biguanides Sales by Application (2023-2028) & (K Pcs)
Table 92. Asia Pacific Antidiabetic Biguanides Revenue by Application (2017-2022) & (US$ Million)
Table 93. Asia Pacific Antidiabetic Biguanides Revenue by Application (2023-2028) & (US$ Million)
Table 94. Asia Pacific Antidiabetic Biguanides Sales by Region (2017-2022) & (K Pcs)
Table 95. Asia Pacific Antidiabetic Biguanides Sales by Region (2023-2028) & (K Pcs)
Table 96. Asia Pacific Antidiabetic Biguanides Revenue by Region (2017-2022) & (US$ Million)
Table 97. Asia Pacific Antidiabetic Biguanides Revenue by Region (2023-2028) & (US$ Million)
Table 98. Latin America Antidiabetic Biguanides Sales by Company (2017-2022) & (K Pcs)
Table 99. Latin America Antidiabetic Biguanides Sales Market Share by Company (2017-2022)
Table 100. Latin America Antidiabetic Biguanides Revenue by Company (2017-2022) & (US$ Million)
Table 101. Latin America Antidiabetic Biguanides Revenue Market Share by Company (2017-2022)
Table 102. Latin America Antidiabetic Biguanides Sales by Type (2017-2022) & (K Pcs)
Table 103. Latin America Antidiabetic Biguanides Sales by Type (2023-2028) & (K Pcs)
Table 104. Latin America Antidiabetic Biguanides Revenue by Type (2017-2022) & (US$ Million)
Table 105. Latin America Antidiabetic Biguanides Revenue by Type (2023-2028) & (US$ Million)
Table 106. Latin America Antidiabetic Biguanides Sales by Application (2017-2022) & (K Pcs)
Table 107. Latin America Antidiabetic Biguanides Sales by Application (2023-2028) & (K Pcs)
Table 108. Latin America Antidiabetic Biguanides Revenue by Application (2017-2022) & (US$ Million)
Table 109. Latin America Antidiabetic Biguanides Revenue by Application (2023-2028) & (US$ Million)
Table 110. Latin America Antidiabetic Biguanides Sales by Country (2017-2022) & (K Pcs)
Table 111. Latin America Antidiabetic Biguanides Sales by Country (2023-2028) & (K Pcs)
Table 112. Latin America Antidiabetic Biguanides Revenue by Country (2017-2022) & (US$ Million)
Table 113. Latin America Antidiabetic Biguanides Revenue by Country (2023-2028) & (US$ Million)
Table 114. Middle East and Africa Antidiabetic Biguanides Sales by Company (2017-2022) & (K Pcs)
Table 115. Middle East and Africa Antidiabetic Biguanides Sales Market Share by Company (2017-2022)
Table 116. Middle East and Africa Antidiabetic Biguanides Revenue by Company (2017-2022) & (US$ Million)
Table 117. Middle East and Africa Antidiabetic Biguanides Revenue Market Share by Company (2017-2022)
Table 118. Middle East and Africa Antidiabetic Biguanides Sales by Type (2017-2022) & (K Pcs)
Table 119. Middle East and Africa Antidiabetic Biguanides Sales by Type (2023-2028) & (K Pcs)
Table 120. Middle East and Africa Antidiabetic Biguanides Revenue by Type (2017-2022) & (US$ Million)
Table 121. Middle East and Africa Antidiabetic Biguanides Revenue by Type (2023-2028) & (US$ Million)
Table 122. Middle East and Africa Antidiabetic Biguanides Sales by Application (2017-2022) & (K Pcs)
Table 123. Middle East and Africa Antidiabetic Biguanides Sales by Application (2023-2028) & (K Pcs)
Table 124. Middle East and Africa Antidiabetic Biguanides Revenue by Application (2017-2022) & (US$ Million)
Table 125. Middle East and Africa Antidiabetic Biguanides Revenue by Application (2023-2028) & (US$ Million)
Table 126. Middle East and Africa Antidiabetic Biguanides Sales by Country (2017-2022) & (K Pcs)
Table 127. Middle East and Africa Antidiabetic Biguanides Sales by Country (2023-2028) & (K Pcs)
Table 128. Middle East and Africa Antidiabetic Biguanides Revenue by Country (2017-2022) & (US$ Million)
Table 129. Middle East and Africa Antidiabetic Biguanides Revenue by Country (2023-2028) & (US$ Million)
Table 130. Pfizer Corporation Information
Table 131. Pfizer Description and Overview
Table 132. Pfizer Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 133. Pfizer Antidiabetic Biguanides Product and Services
Table 134. Pfizer Antidiabetic Biguanides SWOT Analysis
Table 135. Pfizer Recent Developments
Table 136. AstraZeneca Corporation Information
Table 137. AstraZeneca Description and Overview
Table 138. AstraZeneca Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 139. AstraZeneca Antidiabetic Biguanides Product and Services
Table 140. AstraZeneca Antidiabetic Biguanides SWOT Analysis
Table 141. AstraZeneca Recent Developments
Table 142. GlaxoSmithKline Corporation Information
Table 143. GlaxoSmithKline Description and Overview
Table 144. GlaxoSmithKline Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 145. GlaxoSmithKline Antidiabetic Biguanides Product and Services
Table 146. GlaxoSmithKline Antidiabetic Biguanides SWOT Analysis
Table 147. GlaxoSmithKline Recent Developments
Table 148. Merck & Co Corporation Information
Table 149. Merck & Co Description and Overview
Table 150. Merck & Co Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 151. Merck & Co Antidiabetic Biguanides Product and Services
Table 152. Merck & Co Antidiabetic Biguanides SWOT Analysis
Table 153. Merck & Co Recent Developments
Table 154. Eli Lilly Corporation Information
Table 155. Eli Lilly Description and Overview
Table 156. Eli Lilly Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 157. Eli Lilly Antidiabetic Biguanides Product and Services
Table 158. Eli Lilly Antidiabetic Biguanides SWOT Analysis
Table 159. Eli Lilly Recent Developments
Table 160. Sanofi Corporation Information
Table 161. Sanofi Description and Overview
Table 162. Sanofi Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 163. Sanofi Antidiabetic Biguanides Product and Services
Table 164. Sanofi Antidiabetic Biguanides SWOT Analysis
Table 165. Sanofi Recent Developments
Table 166. Takeda Pharmaceuticals Corporation Information
Table 167. Takeda Pharmaceuticals Description and Overview
Table 168. Takeda Pharmaceuticals Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 169. Takeda Pharmaceuticals Antidiabetic Biguanides Product and Services
Table 170. Takeda Pharmaceuticals Antidiabetic Biguanides SWOT Analysis
Table 171. Takeda Pharmaceuticals Recent Developments
Table 172. Novo Nordisk Corporation Information
Table 173. Novo Nordisk Description and Overview
Table 174. Novo Nordisk Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 175. Novo Nordisk Antidiabetic Biguanides Product and Services
Table 176. Novo Nordisk Antidiabetic Biguanides SWOT Analysis
Table 177. Novo Nordisk Recent Developments
Table 178. Servier Laboratories Corporation Information
Table 179. Servier Laboratories Description and Overview
Table 180. Servier Laboratories Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 181. Servier Laboratories Antidiabetic Biguanides Product and Services
Table 182. Servier Laboratories Antidiabetic Biguanides SWOT Analysis
Table 183. Servier Laboratories Recent Developments
Table 184. Boehringer Ingelheim Corporation Information
Table 185. Boehringer Ingelheim Description and Overview
Table 186. Boehringer Ingelheim Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 187. Boehringer Ingelheim Antidiabetic Biguanides Product and Services
Table 188. Boehringer Ingelheim Antidiabetic Biguanides SWOT Analysis
Table 189. Boehringer Ingelheim Recent Developments
Table 190. Bristol-Myers Squibb Corporation Information
Table 191. Bristol-Myers Squibb Description and Overview
Table 192. Bristol-Myers Squibb Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 193. Bristol-Myers Squibb Antidiabetic Biguanides Product and Services
Table 194. Bristol-Myers Squibb Recent Developments
Table 195. Key Raw Materials Lists
Table 196. Raw Materials Key Suppliers Lists
Table 197. Antidiabetic Biguanides Distributors List
Table 198. Antidiabetic Biguanides Customers List
Table 199. Research Programs/Design for This Report
Table 200. Key Data Information from Secondary Sources
Table 201. Key Data Information from Primary Sources
List of Figures
Figure 1. Antidiabetic Biguanides Pr

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Metformin Hydrochloride Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104

Metformin hydrochloride is The raw material of finished product metformin hydrochloride drugs. That is The API metformin hydrochloride. Metformin Hydrochloride finished product is an oral antihyperglycemic drug used in The management of type 2-diabetes. Metformin hydrochloride (N, N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin hydrochloride is a white to off-white crystall......

Global Antidiabetic Sulphonylureas Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 112

Market Overview of Global Antidiabetic Sulphonylureas market: According to our latest research, the global Antidiabetic Sulphonylureas market looks promising in the next 5 years. As of 2022, the global Antidiabetic Sulphonylureas market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of t......

Global Insulin Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101

According to our LPI (LP Information) latest study, the global Insulin market size was valued at US$ million in 2023. With growing demand in downstream market, the Insulin is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Insulin market. Insulin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization......

Global Insulin API Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 116

According to our LPI (LP Information) latest study, the global Insulin API market size was valued at US$ 1707.6 million in 2023. With growing demand in downstream market, the Insulin API is forecast to a readjusted size of US$ 2101.4 million by 2030 with a CAGR of 3.0% during review period. The research report highlights the growth potential of the global Insulin API market. Insulin API are expected to show stable growth in the future market. However, product differentiation, reducing co......

Global Glucagon Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101

According to our LPI (LP Information) latest study, the global Glucagon market size was valued at US$ 543.9 million in 2023. With growing demand in downstream market, the Glucagon is forecast to a readjusted size of US$ 835.7 million by 2030 with a CAGR of 6.3% during review period. The research report highlights the growth potential of the global Glucagon market. Glucagon are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......

Global Acarbose Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95

According to our LPI (LP Information) latest study, the global Acarbose market size was valued at US$ 135.8 million in 2023. With growing demand in downstream market, the Acarbose is forecast to a readjusted size of US$ 165.9 million by 2030 with a CAGR of 2.9% during review period. The research report highlights the growth potential of the global Acarbose market. Acarbose are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......

Global Insulin Glargine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 77

According to our LPI (LP Information) latest study, the global Insulin Glargine market size was valued at US$ 6562.1 million in 2023. With growing demand in downstream market, the Insulin Glargine is forecast to a readjusted size of US$ 8722.5 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Insulin Glargine market. Insulin Glargine are expected to show stable growth in the future market. However, product differen......

Global Liraglutide Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 103

According to our LPI (LP Information) latest study, the global Liraglutide market size was valued at US$ million in 2023. With growing demand in downstream market, the Liraglutide is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Liraglutide market. Liraglutide are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply ch......

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96

According to our LPI (LP Information) latest study, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at US$ 8624.4 million in 2023. With growing demand in downstream market, the Glucagon Like Peptide-1 (GLP-1) Agonists is forecast to a readjusted size of US$ 21310 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. Glucagon Like Peptide-1 (GL......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs